![David Segarra](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Cargos activos de David Segarra
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
AptaTargets SL
![]() AptaTargets SL Pharmaceuticals: MajorHealth Technology AptaTargets SL is a biopharmaceutical company based in Madrid, Spain that focuses on developing therapeutic applications based on aptamer technology. The Spanish company is currently developing aptoll, an immune modulator that blocks the activation of tlr4 in a stroke, representing a novel approach to treat ischemic stroke in the acute phase. It could also be administered in patients up to 48 hours after the stroke. AptaTargets targets indications where inflammation causes significant damage through clinical studies and successful preclinical development. The company was founded in 2014 by David Segarra and María Eugenia Zarabozo, with David Segarra serving as the CEO since then. | Director/Miembro de la Junta | 01/01/2014 | - |
Director Ejecutivo | 01/01/2014 | - | |
Fundador | 01/01/2014 | - |
Historial de carrera de David Segarra
Antiguos cargos conocidos de David Segarra.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Aptus Biotech SL
![]() Aptus Biotech SL BiotechnologyHealth Technology Aptus Biotech SL develops drug candidates using its aptamer platform. It is a biotechnology company specializing in the development and customization of Aptamers fully adapted to the needs of each application. The firm’s product Aptateca, offers a catalog of aptamers. The company was founded by David Segarra and María Eugenia Zarabozo in 2010 and is headquartered in Madrid, Spain. | Director Ejecutivo | 01/01/2010 | - |
Fundador | 01/01/2010 | - |
Estadísticas
Internacional
España | 3 |
Operativa
Chief Executive Officer | 2 |
Founder | 2 |
Director/Board Member | 1 |
Sectorial
Health Technology | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Aptus Biotech SL
![]() Aptus Biotech SL BiotechnologyHealth Technology Aptus Biotech SL develops drug candidates using its aptamer platform. It is a biotechnology company specializing in the development and customization of Aptamers fully adapted to the needs of each application. The firm’s product Aptateca, offers a catalog of aptamers. The company was founded by David Segarra and María Eugenia Zarabozo in 2010 and is headquartered in Madrid, Spain. | Health Technology |
AptaTargets SL
![]() AptaTargets SL Pharmaceuticals: MajorHealth Technology AptaTargets SL is a biopharmaceutical company based in Madrid, Spain that focuses on developing therapeutic applications based on aptamer technology. The Spanish company is currently developing aptoll, an immune modulator that blocks the activation of tlr4 in a stroke, representing a novel approach to treat ischemic stroke in the acute phase. It could also be administered in patients up to 48 hours after the stroke. AptaTargets targets indications where inflammation causes significant damage through clinical studies and successful preclinical development. The company was founded in 2014 by David Segarra and María Eugenia Zarabozo, with David Segarra serving as the CEO since then. | Health Technology |
- Bolsa de valores
- Insiders
- David Segarra
- Experiencia